Inventiva Receives Approval for Financing through Issuance of Shares

Daix, France – Long Island City, New York, United States, October 14, 2024

Inventiva, a clinical-stage biopharmaceutical company with a focus on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs, announced on October 14, 2024 that the Autorité des marchés financiers (AMF) has approved a prospectus under no. 24-432. This approval is in connection with the company’s financing through the issuance of ordinary shares and pre-funded share warrants.

This significant development marks an important step for Inventiva as it seeks to raise funds to support its ongoing research and development efforts in the field of biopharmaceuticals. The approval from the AMF gives the company the green light to proceed with its planned financial activities, which will enable it to accelerate its work towards finding innovative therapies for patients in need.

Impact on Individuals

For individuals, this approval signifies a potential opportunity to invest in a company that is dedicated to addressing serious medical conditions and improving the lives of patients. By supporting Inventiva through the purchase of shares or warrants, investors have the chance to contribute to the development of new treatments that could have a positive impact on their own health or the health of loved ones.

Impact on the World

On a larger scale, the approval of Inventiva’s financing prospectus has the potential to benefit the world by advancing research and development in the field of biopharmaceuticals. By providing additional funding for Inventiva’s activities, the company may be able to accelerate the discovery of novel therapies for a range of diseases, ultimately improving healthcare outcomes globally.

Conclusion

Inventiva’s approval for financing through the issuance of shares and pre-funded share warrants represents a significant milestone for the company and the field of biopharmaceuticals as a whole. This development opens up new opportunities for investors, individuals, and the world at large, as it paves the way for continued innovation and progress in the fight against serious diseases. As we look towards the future, we can expect to see Inventiva making further strides in its mission to advance healthcare and improve patient outcomes.